Visceral Fat Around the Lungs: Risks and Treatment

Visceral fat around the lungs is a metabolically active form of deep body fat that accumulates within the thoracic cavity, surrounding vital respiratory and cardiac structures. Unlike subcutaneous fat, it secretes inflammatory proteins and can physically restrict lung expansion, contributing to breathlessness, reduced lung capacity, and conditions such as obstructive sleep apnoea and obesity hypoventilation syndrome. Understanding how this fat affects breathing, how it is diagnosed within the NHS, and what treatments are available is essential for anyone concerned about the respiratory and cardiovascular consequences of central adiposity.

What is visceral fat around the lungs and why does it matter?

Visceral fat around the lungs is metabolically active adipose tissue in the thoracic cavity that secretes inflammatory proteins and may compress respiratory structures, contributing to reduced lung function and systemic disease. BMI alone does not reliably reflect its presence.

Visceral fat around the lungs refers to metabolically active adipose tissue that accumulates in and around the thoracic cavity, including deposits within the chest wall, around the diaphragm, and in the mediastinum (the space between the lungs). Unlike subcutaneous fat, which sits just beneath the skin, visceral fat is embedded deep within the body and surrounds vital organs.

This type of fat is not simply inert storage tissue. It actively secretes inflammatory proteins, including cytokines and adipokines, which are associated with disrupted organ function and systemic inflammation.^[1][2] These biological effects are well described in the medical literature, though the precise mechanisms continue to be studied. When deposits accumulate near or around the lungs, they may physically compress respiratory structures and alter the mechanical properties of breathing.

Research published in journals including the European Respiratory Journal has highlighted specific fat depots, such as pericardial fat (around the heart) and paracardial fat, both of which sit in close proximity to the lungs and have been associated with reduced lung function. Intrathoracic fat more broadly has been associated with conditions including asthma, chronic obstructive pulmonary disease (COPD), and obstructive sleep apnoea, though these are associations rather than established causal relationships.

It is important to understand that body mass index (BMI) alone does not reliably reflect the amount of visceral fat a person carries. Someone with a normal BMI may still carry significant visceral fat deposits, while the reverse can also be true. This makes clinical assessment and, where appropriate, imaging particularly valuable in understanding an individual's metabolic and respiratory risk profile.

How does fat around the lungs affect your breathing and health?

Thoracic visceral fat reduces lung capacity by restricting diaphragm movement and lowering forced vital capacity, and its inflammatory mediators are associated with airway hyperresponsiveness, sleep apnoea, and cardiovascular conditions including atrial fibrillation.

Fat deposits around the lungs may impair breathing through several distinct mechanisms, both mechanical and inflammatory. Physically, excess thoracic fat reduces the space available for the lungs to expand fully during inhalation, lowering what clinicians call total lung capacity and forced vital capacity (FVC). This can produce a restrictive pattern of breathing, where the lungs cannot inflate to their normal volume.

The diaphragm, the primary muscle of respiration, is particularly vulnerable. When visceral fat accumulates in the abdominal and lower thoracic regions, it pushes upward against the diaphragm, especially when lying flat. This is one reason why people with central obesity frequently report worsening breathlessness at rest or during sleep, and it is a recognised driver of obesity hypoventilation syndrome (OHS), a serious condition in which the body cannot breathe adequately, leading to low oxygen and raised carbon dioxide levels in the blood. Diagnosis of OHS typically requires arterial blood gas measurement or serum bicarbonate screening alongside a sleep study, as outlined in NICE guideline NG202.^[6][7]

Beyond mechanics, the inflammatory mediators released by visceral fat are associated with airway inflammation. Studies have found associations between higher intrathoracic fat volumes and increased airway hyperresponsiveness, which may worsen asthma in susceptible individuals, though causation has not been firmly established. Visceral fat is also associated with obstructive sleep apnoea, where the upper airway collapses repeatedly during sleep, causing oxygen desaturation and fragmented rest.

The cardiovascular consequences are also significant. Pericardial and paracardial fat deposits have been associated in observational studies with:

• Atrial fibrillation

• Coronary artery disease

• Heart failure with preserved ejection fraction

These associations are described in cardiovascular literature including reviews published in the Journal of the American College of Cardiology. These conditions can further compromise respiratory function, creating a cycle that is difficult to break without targeted intervention.

How do doctors in the UK diagnose fat deposits around the lungs?

UK clinicians use waist-to-height ratio, spirometry, and pulse oximetry as initial assessments, with CT or MRI imaging and sleep studies arranged where obesity hypoventilation syndrome or sleep apnoea is suspected, guided by NICE NG201 and NG202.

UK doctors diagnose thoracic and visceral fat deposits using a combination of clinical assessment, functional testing, and imaging, guided by NICE recommendations and local clinical pathways. No single test is definitive, and the approach is usually tailored to the individual's symptoms and risk factors.

Initial assessment typically involves:

• Waist circumference measurement, which is a practical proxy for central adiposity. NICE guideline NG201 (Obesity: identification, assessment and management) recommends using waist-to-height ratio as a preferred measure of central adiposity, with a ratio above 0.5 indicating increased risk. Where waist circumference is used, ethnicity-specific thresholds apply, as metabolic risk differs between ethnic groups at the same waist measurement. A GP can advise on the most appropriate measure for an individual.

• Spirometry, which measures lung volumes and airflow. In obesity, a restrictive pattern (reduced lung volumes with preserved airflow ratios) is most common. An obstructive pattern, where airflow is reduced relative to lung volume, usually suggests a coexisting airway condition such as asthma or COPD rather than adiposity alone.

• Pulse oximetry, to assess resting oxygen saturation, particularly if obesity hypoventilation syndrome is suspected. Where OHS is a concern, serum bicarbonate or arterial blood gas measurement and a sleep study are usually required to confirm the diagnosis, in line with NICE NG202.

Where more detailed information is needed, a GP may refer for imaging. Computed tomography (CT) scanning provides precise measurements of fat compartments around the lungs, heart, and mediastinum and is widely used in research to quantify visceral and intrathoracic fat. However, CT involves ionising radiation and is not used routinely for this purpose alone. Magnetic resonance imaging (MRI) offers an alternative without radiation and is increasingly used in both research and clinical settings. Neither modality is arranged solely to measure fat without another clinical indication.

Echocardiography may be requested to assess cardiac structure and function where pericardial fat and its cardiac effects are a concern, though it is not a reliable tool for quantifying pericardial fat volume. Sleep studies, including overnight oximetry or polysomnography, are arranged when obstructive sleep apnoea or obesity hypoventilation syndrome is suspected.

Blood tests, including fasting glucose, HbA1c, lipid profile, and liver function, are routinely checked alongside respiratory investigations, as visceral fat is closely associated with type 2 diabetes, dyslipidaemia, and non-alcoholic fatty liver disease.

Can you reduce visceral fat around the lungs through lifestyle changes?

Structured diet and exercise targeting 5 to 10 per cent body weight loss can measurably reduce visceral fat and improve lung function; NHS guidelines recommend at least 150 minutes of moderate aerobic activity weekly alongside muscle-strengthening exercise.

Visceral fat, including thoracic deposits, tends to respond to lifestyle intervention, and structured diet and exercise changes are a well-supported first-line strategy. Evidence from systematic reviews and clinical trials suggests that even modest weight loss of 5 to 10 per cent of body weight can produce measurable reductions in visceral fat and improvements in lung function, though individual responses vary.

Dietary changes are central to any plan. A calorie-controlled diet that emphasises whole grains, vegetables, lean protein, and healthy fats (consistent with a Mediterranean-style pattern) has been associated with reductions in visceral adiposity. Reducing ultra-processed foods, added sugars, and excess alcohol is particularly important, as these are associated with central fat accumulation.

Physical activity has an effect on visceral fat beyond its role in calorie expenditure. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training are associated with reductions in visceral fat stores. UK Chief Medical Officers' guidelines, reflected in NHS guidance, recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days.^[12][13] Even incremental increases in daily movement are beneficial for those who are deconditioned.

Sleep quality matters too. Poor sleep and untreated sleep apnoea are associated with increased visceral fat accumulation, with hormonal factors including changes in cortisol and appetite-regulating hormones thought to play a role, though the precise mechanisms are still being studied. Addressing sleep disorders can therefore support fat reduction efforts.

Smoking cessation is strongly advised. Although smoking is associated with lower body weight, it is associated with central fat redistribution and worsens respiratory function independently. NHS Stop Smoking Services offer free, evidence-based support and can be accessed through a GP or directly via the NHS website.

For many people, sustained lifestyle change is challenging without structured support, and referral to a tier 2 or tier 3 weight management service through a GP can provide the multidisciplinary input needed.

Medical treatments and NHS support for excess visceral fat

Licensed NHS options include orlistat, semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro), with eligibility determined by NICE criteria; GLP-1 receptor agonists carry risks of pancreatitis and gallbladder disease requiring patient awareness.

When lifestyle changes alone are insufficient, medical treatments and structured NHS programmes can provide additional support for reducing visceral fat and its respiratory consequences. NICE technology appraisals and clinical guidelines outline criteria for pharmacological and surgical interventions within the NHS, and eligibility is determined by a clinician based on individual circumstances, including BMI, comorbidities, and previous treatment history.

Licensed weight-management medicines available in the UK include:

• Orlistat, a lipase inhibitor available on NHS prescription and over the counter, which reduces dietary fat absorption.^[26]

• Semaglutide injection (Wegovy), a GLP-1 receptor agonist authorised by the MHRA for chronic weight management, given by subcutaneous injection in doses up to 2.4 mg weekly (and up to 7.2 mg weekly at the highest licensed maintenance dose). NICE technology appraisal TA875 sets out NHS eligibility criteria for semaglutide in weight management.

• Liraglutide injection (Saxenda), a GLP-1 receptor agonist authorised for weight management by subcutaneous injection.

• Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist authorised by the MHRA for both type 2 diabetes and chronic weight management. Clinical trial data demonstrate substantial reductions in total and visceral adiposity. The relevant NICE technology appraisal for tirzepatide in weight management should be consulted for current NHS eligibility criteria.

• Oral semaglutide (Wegovy 25 mg tablets), authorised by the MHRA for weight management. This is a different product from Rybelsus and has its own licensed posology.

Key safety information for GLP-1 and dual GIP/GLP-1 receptor agonists: these medicines are associated with gastrointestinal side effects including nausea, vomiting, and diarrhoea, particularly when starting treatment. Acute pancreatitis has been reported with this medicine class, including severe and necrotising cases; patients should be aware of the symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back) and seek urgent medical attention if these occur. Gallbladder disease, including gallstones and cholecystitis, has also been reported. In people with pre-existing diabetic retinopathy, rapid improvement in glycaemic control has been associated with worsening of retinopathy; this subgroup requires careful monitoring.^[21][22]

These medicines are not suitable for everyone. They are not recommended during pregnancy or breastfeeding; patients planning a pregnancy should discuss stopping treatment with their prescriber in advance. For tirzepatide specifically, the UK SmPC advises that people using oral contraceptives should use an additional non-oral contraceptive method for four weeks after starting treatment and for four weeks after each dose increase, because delayed gastric emptying may reduce oral contraceptive absorption.^[24][25]

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support. Medicines such as those listed above are only prescribed where clinically appropriate following individual assessment.

Bariatric surgery remains the most effective long-term intervention for severe obesity and is commissioned by NHS Integrated Care Boards (ICBs) for eligible patients, in line with NICE guidance on obesity management. Continuous positive airway pressure (CPAP) therapy is the standard NHS treatment for obstructive sleep apnoea and can significantly improve respiratory function while weight management is pursued.

Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

When should you see a GP about breathing problems linked to body fat?

See a GP promptly if you have persistent breathlessness at rest or when lying flat, morning headaches, witnessed apnoeas, or ankle swelling with breathlessness; call 999 immediately for sudden severe breathlessness or chest pain.

You should see your GP if you experience persistent or worsening breathlessness that is not explained by a known condition, particularly if it occurs at rest, during minimal exertion, or when lying flat. These symptoms may indicate that visceral fat is mechanically or physiologically affecting your respiratory function and warrant prompt clinical evaluation.

Specific symptoms that should prompt a GP appointment include:

• Breathlessness that wakes you from sleep or that is worse when lying down (orthopnoea)

• Loud snoring, witnessed pauses in breathing during sleep, or excessive daytime sleepiness, which may suggest obstructive sleep apnoea

• Morning headaches, which can be a sign of overnight carbon dioxide retention in obesity hypoventilation syndrome

• Persistent cough or wheeze that has not been investigated, especially in the context of central obesity

• Ankle swelling combined with breathlessness, which may indicate heart or lung strain, for example from heart failure or pulmonary hypertension, and should be assessed promptly

If you develop sudden severe breathlessness, chest pain, or feel faint, call 999 immediately, as these may indicate a life-threatening emergency such as pulmonary embolism or acute cardiac event.

For non-urgent concerns about weight and its effect on your breathing, contact NHS 111 for guidance on the most appropriate next step if you are unsure whether your symptoms need same-day attention.

Your GP can arrange spirometry, blood tests, and referral to respiratory or weight management services as appropriate. Early assessment is valuable because the respiratory consequences of visceral fat are often underdiagnosed, and effective treatments are available. Do not wait until symptoms are severe before seeking advice.

Scientific References

1. Crosstalk between visceral adipose tissue secretome and tumoral microenvironment in obesity-induced colorectal cancer.
2. Male Obesity and Cardiometabolic Risk: Inflammatory Mechanisms and Clinical Implications.
3. Intrathoracic Adipose Tissue and Airway Structure, Lung Function, and Respiratory Symptoms: The Framingham Heart Study.
4. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study.
5. Pericardial fat is associated with impaired lung function and a restrictive lung pattern in adults: the Jackson Heart Study.
6. NG202 – Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s: Chapter 2 – Obesity hypoventilation syndrome.
7. NG202 Visual summary: OHS investigations and treatment.
8. The Role of Pericardial Fat in Cardiometabolic Disease: Emerging Evidence and Therapeutic Potential.
9. Epicardial Adipose Tissue: A Precise Biomarker for Cardiovascular Risk, Metabolic Diseases, and Target for Therapeutic Interventions.
10. The Role of Echocardiography in the Assessment of Epicardial Adipose Tissue: A Systematic Review and Meta-analysis.
11. NG246 – Overweight and obesity management: Identifying and assessing overweight, obesity and central adiposity.
12. Physical activity guidelines for adults aged 19 to 64.
13. UK Chief Medical Officers' Physical Activity Guidelines.
14. TA875 – Semaglutide for managing overweight and obesity: Overview.
15. TA875 – Semaglutide for managing overweight and obesity: Chapter 1 Recommendations.
16. First GLP-1 tablet for weight loss approved in the UK (oral semaglutide).
17. Mounjaro (tirzepatide) – European Medicines Agency EPAR.
18. TA1026 – Tirzepatide for managing overweight and obesity: Practical guide.
19. Tirzepatide (Mounjaro) – NHS medicines information.
20. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
21. Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.
22. Retinal Outcomes in Diabetes: Antihyperglycemic Therapy, EWDR, and Perioperative Considerations.
23. Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide – a review.
24. Tirzepatide – BNF drug monograph.
25. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraceptive absorption (Skelley JW et al.).
26. Orlistat: a medicine to treat obesity.

Frequently Asked Questions